PD-1/PD-L1

Inhibitory Selectivity

PD-1/PD-L1 Products

All (8) PD-1/PD-L1 Inhibitors (8) PD-1/PD-L1 Antibodies (3) New PD-1/PD-L1 Products

Catalog No.	Information	Product Use Citations	Product Validations
A2002	Nivolumab (anti-PD-1) Nivolumab (anti-PD-1) is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. MW : 143.597 KD.	Clin Cancer Res, 2019, 10.1158/1078-0432 PLoS Pathog, 2019, 15(1):e1007468 Ann Surg Oncol, 2019, 26(1):139-147	Apoptosis rates of Jurkat cells co-cultured for 72 h with H1975, A549 cells or H1975 with 10 μg/mL nivolumab were analyzed by Annexin V-FITC/PI assay (Left) and quantified (Right).
A2004	Atezolizumab (anti-PD-L1) Atezolizumab (anti-PD-L1) is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1. MW : 145 KD.	Nat Biotechnol, 2019, 10.1038/s41587-019-0262-4 J Immunother Cancer, 2019, 7(1):245 J Exp Clin Cancer Res, 2019, 38(1):253
A2005	Pembrolizumab (anti-PD-1) Pembrolizumab (anti-PD-1) is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. MW : 146.286 KD.	J Oral Pathol Med, 2019, 10.1111/jop.12906 Ann Surg Oncol, 2019, 26(1):139-147 Journal of Oral Pathology & Medicine, 2019, 10.1111/jop.12906
S8158	PD-1/PD-L1 Inhibitor 3 PD-1/PD-L1 Inhibitor 3（Programmed Death-1/Programmed Death-Ligand 1 Inhibitor 3）is a Macrocyclic inhibitor of PD-1/PD-L1 interaction with IC50 of 5.6 nM
S7912	BMS202 (PD-1/PD-L1 inhibitor 2) BMS202 (PD-1/PD-L1 inhibitor 2) is a small-molecule PD-1/PD-L1 interaction inhibitor with IC50 of 18 nM.
S8549	AUNP-12 AUNP-12, a new immune checkpoint modulator, is an inhibitor of the PD-1 pathway.
S8859^New	BMS-1166 BMS-1166 is a novel and potent small molecule inhibitor of the PD-1/PD-L1 interaction with an IC50 of 1.4 nM.
S7911	PD-1/PD-L1 inhibitor 1 PD-1/PD-L1 inhibitor 1 is a small-molecule inhibitor of PD-1/PD-L1 interaction with IC50 of 6 nM.

Catalog No.	Information	Product Use Citations	Product Validations
A2002	Nivolumab (anti-PD-1) Nivolumab (anti-PD-1) is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. MW : 143.597 KD.	Clin Cancer Res, 2019, 10.1158/1078-0432 PLoS Pathog, 2019, 15(1):e1007468 Ann Surg Oncol, 2019, 26(1):139-147	Apoptosis rates of Jurkat cells co-cultured for 72 h with H1975, A549 cells or H1975 with 10 μg/mL nivolumab were analyzed by Annexin V-FITC/PI assay (Left) and quantified (Right).
A2004	Atezolizumab (anti-PD-L1) Atezolizumab (anti-PD-L1) is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1. MW : 145 KD.	Nat Biotechnol, 2019, 10.1038/s41587-019-0262-4 J Immunother Cancer, 2019, 7(1):245 J Exp Clin Cancer Res, 2019, 38(1):253
A2005	Pembrolizumab (anti-PD-1) Pembrolizumab (anti-PD-1) is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. MW : 146.286 KD.	J Oral Pathol Med, 2019, 10.1111/jop.12906 Ann Surg Oncol, 2019, 26(1):139-147 Journal of Oral Pathology & Medicine, 2019, 10.1111/jop.12906
S8158	PD-1/PD-L1 Inhibitor 3 PD-1/PD-L1 Inhibitor 3（Programmed Death-1/Programmed Death-Ligand 1 Inhibitor 3）is a Macrocyclic inhibitor of PD-1/PD-L1 interaction with IC50 of 5.6 nM
S7912	BMS202 (PD-1/PD-L1 inhibitor 2) BMS202 (PD-1/PD-L1 inhibitor 2) is a small-molecule PD-1/PD-L1 interaction inhibitor with IC50 of 18 nM.
S8549	AUNP-12 AUNP-12, a new immune checkpoint modulator, is an inhibitor of the PD-1 pathway.
S8859^New	BMS-1166 BMS-1166 is a novel and potent small molecule inhibitor of the PD-1/PD-L1 interaction with an IC50 of 1.4 nM.
S7911	PD-1/PD-L1 inhibitor 1 PD-1/PD-L1 inhibitor 1 is a small-molecule inhibitor of PD-1/PD-L1 interaction with IC50 of 6 nM.

Catalog No.	Information	Product Use Citations	Product Validations
A2013	Durvalumab (anti-PD-L1) Durvalumab (anti-PD-L1) is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa.
A2016	Camrelizumab (anti-PD-1) Camrelizumab (anti-PD-1) is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1 with immune checkpoint inhibitory and antineoplastic activities.
A2017	Spartalizumab (anti-PD-1) Spartalizumab (anti-PD-1) is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1. It binds to PD-1 with high affinity and inhibits the biological activity of PD-1.

Catalog No.

Information

Product Use Citations

Product Validations

A2013

Durvalumab (anti-PD-L1)

Durvalumab (anti-PD-L1) is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa.

A2016

Camrelizumab (anti-PD-1)

Camrelizumab (anti-PD-1) is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1 with immune checkpoint inhibitory and antineoplastic activities.

A2017

Spartalizumab (anti-PD-1) is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1. It binds to PD-1 with high affinity and inhibits the biological activity of PD-1.

Choose Your Country or Region

By Signaling Pathways

By product type

PD-1/PD-L1

Inhibitory Selectivity

PD-1/PD-L1 Products

Nivolumab (anti-PD-1)

Atezolizumab (anti-PD-L1)

Pembrolizumab (anti-PD-1)

PD-1/PD-L1 Inhibitor 3

BMS202 (PD-1/PD-L1 inhibitor 2)

AUNP-12

BMS-1166

PD-1/PD-L1 inhibitor 1